So, three good weeks in a row for biotechs. In fact this week might qualify as the best week to date for the year. The NASDAQ Composite cooled off a little from the previous week, still a positive return of 2.2%. But in contrast to last week, the Biotech Indices blew the broader market out of the water, with gains of 6.8% and 13.8% for the NASDAQ and Standard and Poor’s Biotech indices.
The top four individual stocks were up more than 50% for the week!!! [Imagine showers of confetti and a ticker tape parade. ;-)]
The number one stock, TOMDF, up more than 84% for the week, based, it seems, on a train of press releases touting their (future) contribution to testing/treating monkey pox, long covid, and the post-treatment Covid “rebound” after using Paxlovid.
[Disclaimer: In my experience, companies claiming to have an “in” on future contributions to every hot new trend often turn out to be grasping at straws. This is my opinion and my opinion only, so don’t take me to court.]
Second place AVLR (up 69%) seems to have its run based on rumors of upcoming earnings beating analyst’s expectations. On the down side, OTIC’s -76% slide was actually due to science, as this week they reported that a phase-2 trial of their tinnnitus treatment was stopped early, showing no benefit versus placebo.
The contest participant’s picks were generally on the money, with the portfolios’ median 10% gain for the week. The number one portfolio’s performance for this week , BRENDAN_49 (up 24%), is not just a one-time fluke: this is the fifth straight week where their YTD standings improved, reaching the number two YTD spot this week. In fact four of the best 10 portfolios, YTD, were also in this week’s top ten list.
There was a fair bit of movement in the YTD top ten list this week. The occupant of the very top spot, DIEGOSAN, unchanged since April 1, still offers a change: Their portfolio is in the black for the year! It’s only the fifth time this year that any portfolio’s YTD performance has been in the black. :-(
A.J. MULLEN (YTD down -22%, for the week up +20% 2nd place) has returned to the list after a five week absence, and BULBAMAN (up 13% for the week, in seventh) has made the list for the first time this year. Special Congratulations to both.
|
Report Time Ranges
|
|
|
From
|
To
|
Recent
|
7/29/22
|
8/5/2022
|
YTD
|
12/31/21
|
Index Performance
|
|
Symbol
|
Recent
|
YTD
|
|
^IXIC
|
2.15%
|
-19.10%
|
^NBI
|
6.83%
|
-11.83%
|
^SPSIBI
|
13.83%
|
-17.51%
|
Share Performance
|
Recent
|
YTD
|
Top 5
|
Bottom 5
|
Top 5
|
Bottom 5
|
TOMDF
|
84.483%
|
OTIC
|
-75.664%
|
OPTN
|
127.16%
|
GNCA
|
-99.04%
|
ALVR
|
69.063%
|
KZIA
|
-48.760%
|
CBIO
|
104.60%
|
VLON
|
-93.33%
|
ALNY
|
53.886%
|
MACK
|
-14.735%
|
ALDX
|
73.00%
|
PTE
|
-89.51%
|
IMUX
|
50.565%
|
LRMR
|
-14.525%
|
FENC
|
58.98%
|
PRQR
|
-89.49%
|
FBIO
|
40.600%
|
SYNH
|
-14.127%
|
IONS
|
50.18%
|
LRMR
|
-85.82%
|
|
Top 10 Portfolio YTD
|
YTD(Portfolio - SPSIBI)
|
Rec
|
Rec(Port. - SPSIBI)
|
DIEGOSAN
|
3.79%
|
21.30%
|
1.065%
|
-12.766%
|
BRENDAN_49
|
-7.05%
|
10.45%
|
0.731%
|
-13.100%
|
DEW DILIGENCE
|
-7.54%
|
9.97%
|
0.806%
|
-13.025%
|
TECHNETIUM
|
-15.45%
|
2.05%
|
-1.784%
|
-15.615%
|
GENEGURU
|
-17.59%
|
-0.08%
|
-2.015%
|
-15.846%
|
A.J. MULLEN
|
-19.06%
|
-1.55%
|
-7.638%
|
-21.469%
|
JACK HARTMANN
|
-20.43%
|
-2.92%
|
2.166%
|
-11.665%
|
BIOSCIENTISTSA
|
-21.86%
|
-4.35%
|
-1.822%
|
-15.653%
|
TAMBORELLI
|
-22.16%
|
-4.65%
|
-1.958%
|
-15.789%
|
BULBAMAN
|
-22.43%
|
-4.93%
|
1.309%
|
-12.522%
|
Average and Median Portfolio Performance
|
|
Avg Recent
|
Avg YTD
|
Median Recent
|
Median YTD
|
|
$5,338
|
-30.38%
|
ETHAN H
|
$6,320
|
RAJU_BIJLEE
|
-32.09%
|
8.05%
|
TAMBORELLI
|
9.993%
|
|
